Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug

Status Recruiting

Clinical Trial Summary

Multidrug resistant tuberculosis (MDR-TB) is difficult to treat and raises a great challenge to TB control program. That pyrazinamide can shorten the course of treatment and facilitate bacilli clearance has been proved recently. In 2011, WHO recommended to use pyrazinamide throughout the course of treatment for MDR-TB. However, pyrazinamide susceptibility testing has not been widely used in clinic. And the conventional testing is time-consuming and unreliable. In contrast, the detection of pncA and rpsA mutations with molecular methods can provide rapid results of pyrazinamide susceptibility. The purpose of this study is to evaluate the efficacy of the introduce the molecular testing of pyrazinamide susceptibility in optimizing the MDR-TB treatment regimen.

Clinical Trial Description

This is a phase 3, open labeled, prospective cohort study to evaluate the molecular testing of pyrazinamide susceptibility in optimizing the MDR-TB treatment regimen. Approximately 100 participants will be given the molecular detection of pncA and rpsA mutations and divide into to the pyrazinamide sensitive comparator group and the pyrazinamide resistant group based on the susceptibility results. For the pyrazinamide sensitive group, the regimen contains six months of chemotherapy with pyrazinamide, amikacin, levofloxacin, plus prothionamide, followed by six months of pyrazinamide, levofloxacin, clarithromycin, plus prothionamide. For the pyrazinamide resistant group, the regimen contains six months of chemotherapy with isoniazid, amikacin, levofloxacin, plus prothionamide, followed by eighteen months of isoniazid, levofloxacin, clarithromycin, plus prothionamide.

The participants will be followed up to 24 months after the start of the treatment. The primary outcome is the sputum culture conversion and the adverse events. Safety evaluations that will be performed are the routine lab tests, blood glucose, hearing , vital signs, ECG, reporting of adverse events, physical examinations and X-rays. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02120638
Study type	Interventional
Source	Huashan Hospital
Contact	Wenhong Zhang, PhD,MD
Phone	+86 21 52889999
Email	zhangwenhong@fudan.edu.cn
Status	Recruiting
Phase	Phase 3
Start date	April 2014
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05017324` - Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial	N/A
Active, not recruiting	`NCT02496572` - Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan	Phase 3
Completed	`NCT03942354` - Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Completed	`NCT02454205` - An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis	Phase 2/Phase 3
Recruiting	`NCT05081401` - Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
Completed	`NCT01856634` - Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis	Phase 1
Active, not recruiting	`NCT03867136` - Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)	Phase 4
Not yet recruiting	`NCT04484129` - MDR-TB Close Contacts Tracing in China (TCCT Study)
Completed	`NCT00727844` - Linezolid to Treat Extensively-Drug Resistant Tuberculosis	Phase 2
Completed	`NCT01859923` - A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)	Phase 2
Active, not recruiting	`NCT04421495` - Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China	Phase 4
Active, not recruiting	`NCT04717908` - Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS	N/A
Not yet recruiting	`NCT03604848` - NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB	N/A
Recruiting	`NCT05534750` - Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms